FDA Releases Guidance on Generic-Drug Development

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
Volume 11
Issue 10

The agency releases guidance on controlled correspondences related to generic-drug development.

 

As part of the implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA), FDA has released guidance that provides information on the process for submitting correspondence to the agency requesting information related to generic-drug development. The guidance also describes FDA’s process for providing communication related to such correspondence.

Included in the guidance are the definition of a controlled correspondence, guidelines for submitting a controlled correspondence, and information on requests related to inactive ingredients and Q1/Q2 formulation assessment controlled correspondence review disciplines. The guidance also includes information on communications from FDA to requestors that submit controlled correspondence.

Source: FDA

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.